Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint.

Rosenberg, Aaron S; Facon, Thierry; Parikh, Kejal; Chung, Weiyuan; Srinivasan, Shankar; Kotey, Stanley; Tuscano, Joseph

Rosenberg, Aaron S; Facon, Thierry; Parikh, Kejal; Chung, Weiyuan; Srinivasan, Shankar; Kotey, Stanley; Tuscano, Joseph.

Afiliação

Rosenberg AS; Division of Hematology/Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address: asrosenberg@ucdavis.edu.
Facon T; Department of Haematology, Lille University Hospital, Lille, France.
Parikh K; Bristol Myers Squibb, Princeton, NJ.
Chung W; Bristol Myers Squibb, Princeton, NJ.
Srinivasan S; Formerly Celgene Corporation, Summit, NJ.
Kotey S; Formerly Celgene Corporation, Summit, NJ.
Tuscano J; Division of Hematology/Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA; Veterans Administration Northern California Health Care System, Sacramento, CA.

Clin Lymphoma Myeloma Leuk ; 21(5): 345-354.e4, 2021 05.

Article em En | MEDLINE | ID: mdl-33563582

Assuntos

Hipercalcemia/etiologia; Mieloma Múltiplo/mortalidade; Idoso; Idoso de 80 Anos ou mais; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Mieloma Múltiplo/fisiopatologia; Intervalo Livre de Progressão

Palavras-chave

Anemia; Hypercalcemia; Multiple Myeloma; Progression; Renal insufficiency

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipercalcemia / Mieloma Múltiplo Tipo de estudo: Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google